192 related articles for article (PubMed ID: 26862918)
1. Glycosylation of Residue 141 of Subtype H7 Influenza A Hemagglutinin (HA) Affects HA-Pseudovirus Infectivity and Sensitivity to Site A Neutralizing Antibodies.
Alvarado-Facundo E; Vassell R; Schmeisser F; Weir JP; Weiss CD; Wang W
PLoS One; 2016; 11(2):e0149149. PubMed ID: 26862918
[TBL] [Abstract][Full Text] [Related]
2. Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.
Zhang L; Jia N; Li J; Han Y; Cao W; Wang S; Huang Z; Lu S
Hum Vaccin Immunother; 2014; 10(7):1949-58. PubMed ID: 25424804
[TBL] [Abstract][Full Text] [Related]
3. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
4. Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge.
Schmeisser F; Vasudevan A; Verma S; Wang W; Alvarado E; Weiss C; Atukorale V; Meseda C; Weir JP
PLoS One; 2015; 10(1):e0117108. PubMed ID: 25629172
[TBL] [Abstract][Full Text] [Related]
5. Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes.
Prabakaran M; Kumar SR; Raj KV; Wu X; He F; Zhou J; Kwang J
Antiviral Res; 2014 Sep; 109():149-59. PubMed ID: 24997413
[TBL] [Abstract][Full Text] [Related]
6. H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.
Khurana S; Coyle EM; Verma S; King LR; Manischewitz J; Crevar CJ; Carter DM; Ross TM; Golding H
Vaccine; 2014 Nov; 32(48):6421-32. PubMed ID: 25284811
[TBL] [Abstract][Full Text] [Related]
7. Establishment of sandwich ELISA for detecting the H7 subtype influenza A virus.
Chen L; Ruan F; Sun Y; Chen H; Liu M; Zhou J; Qin K
J Med Virol; 2019 Jun; 91(6):1168-1171. PubMed ID: 30680746
[TBL] [Abstract][Full Text] [Related]
8. Glycosylation generates an efficacious and immunogenic vaccine against H7N9 influenza virus.
Kim JI; Park S; Bae JY; Lee S; Kim J; Kim G; Yoo K; Heo J; Kim YS; Shin JS; Park MS; Park MS
PLoS Biol; 2020 Dec; 18(12):e3001024. PubMed ID: 33362243
[TBL] [Abstract][Full Text] [Related]
9. L226Q Mutation on Influenza H7N9 Virus Hemagglutinin Increases Receptor-Binding Avidity and Leads to Biased Antigenicity Evaluation.
Wang Y; Lv Y; Niu X; Dong J; Feng P; Li Q; Xu W; Li J; Li C; Li J; Luo J; Li Z; Liu Y; Tan YJ; Pan W; Chen L
J Virol; 2020 Sep; 94(20):. PubMed ID: 32796071
[TBL] [Abstract][Full Text] [Related]
10. Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.
Stadlbauer D; Amanat F; Strohmeier S; Nachbagauer R; Krammer F
Emerg Microbes Infect; 2018 Jun; 7(1):110. PubMed ID: 29925896
[TBL] [Abstract][Full Text] [Related]
11. Development and optimized pairing of mouse monoclonal antibodies for detecting hemagglutinin in novel H7 subtype influenza viruses.
Wang H; Zhou J; Wang D; Huang B; Tan W
Sci China Life Sci; 2020 Feb; 63(2):279-289. PubMed ID: 31147904
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Mouse Monoclonal Antibodies Against the HA of A(H7N9) Influenza Virus.
Ito M; Yamayoshi S; Murakami K; Saito K; Motojima A; Nakaishi K; Kawaoka Y
Viruses; 2019 Feb; 11(2):. PubMed ID: 30754701
[TBL] [Abstract][Full Text] [Related]
14. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains.
Henry Dunand CJ; Leon PE; Kaur K; Tan GS; Zheng NY; Andrews S; Huang M; Qu X; Huang Y; Salgado-Ferrer M; Ho IY; Taylor W; Hai R; Wrammert J; Ahmed R; García-Sastre A; Palese P; Krammer F; Wilson PC
J Clin Invest; 2015 Mar; 125(3):1255-68. PubMed ID: 25689254
[TBL] [Abstract][Full Text] [Related]
15. Development and applications of universal H7 subtype-specific antibodies for the analysis of influenza H7N9 vaccines.
Gravel C; Elmgren C; Muralidharan A; Hashem AM; Jaentschke B; Xu K; Widdison J; Arnold K; Farnsworth A; Rinfret A; Van Domselaar G; Wang J; Li C; Li X
Vaccine; 2015 Feb; 33(9):1129-34. PubMed ID: 25620245
[TBL] [Abstract][Full Text] [Related]
16. Antigenic Fingerprinting of Antibody Response in Humans following Exposure to Highly Pathogenic H7N7 Avian Influenza Virus: Evidence for Anti-PA-X Antibodies.
Khurana S; Chung KY; Coyle EM; Meijer A; Golding H
J Virol; 2016 Oct; 90(20):9383-93. PubMed ID: 27512055
[TBL] [Abstract][Full Text] [Related]
17. Antigenic Drift of Influenza A(H7N9) Virus Hemagglutinin.
Ning T; Nie J; Huang W; Li C; Li X; Liu Q; Zhao H; Wang Y
J Infect Dis; 2019 Jan; 219(1):19-25. PubMed ID: 29982588
[TBL] [Abstract][Full Text] [Related]
18. A cross-reactive human monoclonal antibody targets the conserved H7 antigenic site A from fifth wave H7N9-infected humans.
Li M; Chen L; Wang Q; Hao M; Zhang X; Liu L; Yu X; Yang C; Xu J; Chen J; Gong R
Antiviral Res; 2019 Oct; 170():104556. PubMed ID: 31299269
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza vaccine.
Gou X; Wu X; Shi Y; Zhang K; Huang J
Hum Vaccin Immunother; 2020; 16(2):286-294. PubMed ID: 31419167
[TBL] [Abstract][Full Text] [Related]
20. Human neutralizing antibodies target a conserved lateral patch on H7N9 hemagglutinin head.
Jia M; Zhao H; Morano NC; Lu H; Lui YM; Du H; Becker JE; Yuen KY; Ho DD; Kwong PD; Shapiro L; To KK; Wu X
Nat Commun; 2024 May; 15(1):4505. PubMed ID: 38802413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
